REG4 serves as a prognostic biomarker for pancreatic cancer with long-standing diabetes mellitus by modulating chemoresistance
Authors:
Open Access
- 2 July 2026
- journal article
- Published by Elsevier in Translational Oncology
- Vol. 71, 102888
Abstract
No abstract availableKeywords
Funding Information
- Korea Health Industry Development Institute
- Yonsei University College of Medicine
- National Research Foundation of Korea
This publication has 36 references indexed in Scilit:
- Targeting CBP revers chemoresistance to 5‐FU of CDX2/REG4 double‐positive gastric cancerClinical and Translational Medicine, 2024
- Prognostic significance of glucose‐lipid metabolic index in pancreatic cancer patients with diabetes mellitusCancer Medicine, 2024
- The impact of diabetes status on total and site-specific cancer risk in the elderly population: A nationwide cohort studyDiabetes Research and Clinical Practice, 2023
- Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerJAMA Oncology, 2022
- The association between diabetes mellitus of different durations and risk of pancreatic cancer: an Australian national data-linkage study in womenCancer Epidemiology, 2022
- Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11p110Cancer Letters, 2021
- Validation of the ENDPAC model: Identifying new-onset diabetics at risk of pancreatic cancerPancreatology, 2021
- Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cellsCancer Letters, 2021
- Longitudinal plasma protein profiling of newly diagnosed type 2 diabetesEBioMedicine, 2021
- Pancreatic cancerThe Lancet, 2020